OpenClinica, LLC, announces the availability of the latest version of its popular open source clinical trials software. The OpenClinica v3.1.3 release contains over 100 fixes and enhancements, including:
These, and many other, advancements are the result of efforts by OpenClinica, LLC and members of the OpenClinica community. “OpenClinica community contributors have helped fuel a lot of the progress reflected in this release,” said Cal Collins, OpenClinica’s CEO. “This release is evidence that a strong open source community can drive the software to a higher quality standard.”
OpenClinica 3.1.3 Community Edition is freely available for download on the OpenClinica community website.
The company also announces that version 3.1.3 of its commercially backed OpenClinica Enterprise Edition is also now available. OpenClinica Enterprise is provided as fully validated, enhanced, and supported implementation of the open source technology, ideal for mission critical environments. This latest rendition of the OpenClinica Enterprise Edition also leverages Akamai’s global content delivery network (CDN), further accelerating the application’s performance.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.